DOI QR코드

DOI QR Code

Update of Research on Drug Resistance in Small Cell Lung Cancer Chemotherapy

  • Chen, Yi-Tian ;
  • Feng, Bing ;
  • Chen, Long-Bang
  • Published : 2012.08.31

Abstract

Small cell lung cancer (SCLC) is characterized by a short cell doubling time, rapid progression and early occurrence of blood-borne and lymph metastasis. The malignancy is the highest of all lung cancer types. Although SCLC has a relatively good initial response to chemotherapy as well as radiotherapy, relapse or disease progression may occur quickly after the initial treatment. Drug resistance, especially multi-drug resistance, is the most important cause of failure of SCLC chemotherapy. This article provides a brief update of research on mechanisms of drug resistance in SCLC and reversal strategies.

Keywords

Small cell lung cancer (SCLC);chemoresistance;targeted therapy

References

  1. Antonia SJ, Mirza N, Fricke I, et al (2006). Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res, 12, 878-87. https://doi.org/10.1158/1078-0432.CCR-05-2013
  2. Coloff JL, Mason EF, Altman BJ, et al (2011). Akt requires glucose metabolism to suppress puma expression and prevent apoptosis of leukemic T cells. J Biol Chem, 286, 5921-33. https://doi.org/10.1074/jbc.M110.179101
  3. Demedts I, Vermaelen K, van Meerbeeck JP (2010). Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J, 35, 202-15. https://doi.org/10.1183/09031936.00105009
  4. Dy GK, Adjei AA (2002). Novel targets for lung cancer therapy: part I. J Clin Oncol, 20, 2881-94. https://doi.org/10.1200/JCO.2002.11.145
  5. Fong KM, Sekido Y, Minna JD (1999) Molecular pathogenesis of lung cancer. J Thor Cardiovas Surg, 118, 1136-52. https://doi.org/10.1016/S0022-5223(99)70121-2
  6. Gemba K, Ueoka H, Kiura K, et al (2000). Immunohistochemical detection of mutant p53 protein in small cell lung cancer: relationship to treatment outcome. Lung Cancer, 29, 23-31,
  7. GUAN Jun ming, YAN Yu sheng, BAI Yi feng, et al (2011). Investigation of multidrug resistant related genes of human SCLC using cDNA microarray. Guangdong Medical Journal, 32, 999-1001.
  8. Guo L, Liu Y, Bai Y, et al (2010). Gene expression profiling of drug-resistant small cell lung cancer cells by combining microRNA and cDNA expression analysis. Eur J Cancer. Jun, 46, 1692-702. https://doi.org/10.1016/j.ejca.2010.02.043
  9. Hann CL, Daniel VC, Sugar EA, et al (2008). Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2 in small cell lung cancer[J]. Cancer Res, 68, 2321-8. https://doi.org/10.1158/0008-5472.CAN-07-5031
  10. Harley ME, Allan LA, Sanderson HS, et al (2010). Phosphorylation of Mcl-1 by CDK1-cyclin B1 initiates its Cdc20-dependent destruction during mitotic arrest. EMBO J, 29, 2407-20. https://doi.org/10.1038/emboj.2010.112
  11. Hodkinson PS, Mackinnon AC, Sethie T (2007 ). Extracellular matrix regulation of drug resistance in small-cell lung. Int. J Radiat Biol, 83, 733-41. https://doi.org/10.1080/09553000701570204
  12. Inoue A, Ishimoto O, Fukumoto S, et al (2010). A phase II study of amrubicin combined with carboplatin for elderly patents with small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0405. Ann Oncol, 21, 800-3. https://doi.org/10.1093/annonc/mdp384
  13. Jackman DM, Johnson BE (2005). Small-cell lung cancer. Lancet, 366, 1385-96. https://doi.org/10.1016/S0140-6736(05)67569-1
  14. Jeong J, Cho BC, Sohn JH, et al (2010). Belotecan for relapsing small cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. Lung Cancer, 70, 77-81. https://doi.org/10.1016/j.lungcan.2010.01.006
  15. Khanzada UK, Pardo OE, Meier C, et al (2006). Potent inhibition of small-cell lung cancer cell growth by simvastatin reveals selective functions of Ras isoforms in growth factor signalling. Oncogene, 25, 877-87. https://doi.org/10.1038/sj.onc.1209117
  16. Knez L;Sodja E; Kern I, et al (2011). Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: a systematic review. Lung Cancer, 72, 271-9. https://doi.org/10.1016/j.lungcan.2011.02.014
  17. Kohmo S, Kijima T, Otani Y, et al (2010). Cell surface tetraspanin CD9 mediates chemoresistance in small cell lung cancer. Cancer Res, 70, 8025-35. https://doi.org/10.1158/0008-5472.CAN-10-0996
  18. Lawson MH, Cummings NM, Rassl DM, et al (2011). Two novel determinants of Etoposide resistance in small cell lung cancer. Cancer Res, 71, 4877-87. https://doi.org/10.1158/0008-5472.CAN-11-0080
  19. Lee SM, James L, Buchler T, et al (2008) .Phase II trial of thalidomide with chemotherapy and as maintenance therapy for patients with poor prognosis small-cell lung cancer. Lung Cancer, 59, 364-8. https://doi.org/10.1016/j.lungcan.2007.08.032
  20. Mason EF, Zhao Y, Goraksha-Hicks P, et al (2010). Aerobic glycolysis suppresses p53 activity to provide selective protection from apoptosis upon loss of growth signals or inhibition of BCR-Abl. Cancer Res, 70, 8066-76. https://doi.org/10.1158/0008-5472.CAN-10-0608
  21. Morimoto H, Tsukada J, Kominato Y, et al (2005). Reduced expression of human mismatch repair genes in adult T-cell leukemia[J]. Am J He-mato, 78, 100-7. https://doi.org/10.1002/ajh.20259
  22. Oltersdorf T, Elmore SW, Shoemaker AR, et al (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature, 435, 677-81. https://doi.org/10.1038/nature03579
  23. Rigas JR, Denham CA, Rinaldi D, et al (2003). Adjuvant targeted therapy in unresectable lung cancer: the results of two randomized placebo-controlled trials of BAY 12-9566, a matrix metalloproteinase inhibitor (MMPI). Lung Cancer. 41, S34.
  24. Roberti A, La Sala D, Cinti C (2006). Multiple genetic and epigenetic interacting mechanisms contribute to clonally selection of drug-resistant tumors: current views and new therapeutic prospective. J Cell Physiol, 207, 571-81. https://doi.org/10.1002/jcp.20515
  25. Rodriguez E, Lilenbaum RC (2010). Small cell lung cancer: past present and future. CurrD Oncol Rep, 12, 327 -34. https://doi.org/10.1007/s11912-010-0120-5
  26. Rudin CM, Kozloff M, Hoffman PC, et al (2004). Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer. J Clin Oncol, 22, 1110-7. https://doi.org/10.1200/JCO.2004.10.148
  27. Sartorius UA and Krammer PH (2002). Upregulation of Bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer, 97, 584-92. https://doi.org/10.1002/ijc.10096
  28. Song Y, Qi Y, Zhang W, et al (2005). Evolutionary trace analysis of eukaryotic DNA topoisomerase I superfamily: identification of novel antitumor drug binding site. Sci China C Life Sci, 48, 375-84. https://doi.org/10.1360/062004-20
  29. Spigel DR, Hainsworth JD, Simons L, et al (2007). Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network. J Thor Oncol, 2, 854-61. https://doi.org/10.1097/JTO.0b013e31814617b7
  30. Tahir SK, Wass J, Joseph MK, et al (2010). Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/ lymphoma cell lines. Mol Cancer Ther, 9, 545-57. https://doi.org/10.1158/1535-7163.MCT-09-0651
  31. Tang CH, Parham C, Shocron E, et al (2011). Picoplatin overcomes resistance to cell toxicity in small cell lung cancer precious treated with cisplatin and carboplatin. Cancer Chemother Pharmacol, 67, 1389-400. https://doi.org/10.1007/s00280-010-1435-5
  32. Tan N, Malek M, Zha J, et al (2011). Navitoclax enhances the efficacy of taxanes in non-small cell lung cancer models. Clin Cancer Res, 17, 1394-404. https://doi.org/10.1158/1078-0432.CCR-10-2353
  33. Weiss RH, Ramirez AL, Joo A (1999). Short-term pravastatin mediates growth inhibition and apoptosis, independently of Ras, via the signaling proteins p27Kip1 and PI3 kinase. J Am Soc Nephrol, 10, 1880-90.
  34. Wertz IE, Kusam S, Lam C, et al (2011). Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature, 471, 110-4. https://doi.org/10.1038/nature09779
  35. Yeh JJ, Hsu NY, Hsu WH, et al (2005). Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung, 183, 177-83. https://doi.org/10.1007/s00408-004-2532-1

Cited by

  1. AP-4 predicts poor prognosis in non-small cell lung cancer vol.10, pp.1, 2014, https://doi.org/10.3892/mmr.2014.2209
  2. Effect and mechanism of Src tyrosine kinase inhibitor sunitinib on the drug-resistance reversal of human A549/DDP cisplatin-resistant lung cancer cell line vol.10, pp.4, 2014, https://doi.org/10.3892/mmr.2014.2440
  3. Optimal Timing of Radiotherapy with Alternating/Sequential Radio-Chemotherapy for Limited-stage Small Cell Lung Cancer vol.15, pp.14, 2014, https://doi.org/10.7314/APJCP.2014.15.14.5697
  4. Timing of Thoracic Radiotherapy in Limited Stage Small Cell Lung Cancer: Results of Early Versus Late Irradiation from a Single Institution in Turkey vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6263
  5. Relationship Between the SER Treatment Period and Prognosis of Patients with Small Cell Lung Cancer vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6415
  6. Over-Expression of Beclin-1 Facilitates Acquired Resistance to Histone Deacetylase Inhibitor-Induced Apoptosis vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7913
  7. Drug Resistance Effects of Ribosomal Protein L24 Overexpression in Hepatocellular Carcinoma HepG2 Cells vol.15, pp.22, 2014, https://doi.org/10.7314/APJCP.2014.15.22.9853
  8. MyD88 expression is associated with paclitaxel resistance in lung cancer A549 cells vol.32, pp.5, 2014, https://doi.org/10.3892/or.2014.3433
  9. Surfactant-based drug delivery systems for treating drug-resistant lung cancer pp.1521-0464, 2014, https://doi.org/10.3109/10717544.2014.935530
  10. Smoking, inflammation and small cell lung cancer: recent developments vol.165, pp.19-20, 2015, https://doi.org/10.1007/s10354-015-0381-6
  11. Analysis of novel microRNA targets in drug-sensitive and -insensitive small cell lung cancer cell lines vol.35, pp.3, 2015, https://doi.org/10.3892/or.2015.4487
  12. Pharmacophore Development for Anti-Lung Cancer Drugs vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8307
  13. Optimal drugs for second-line treatment of patients with small-cell lung cancer vol.17, pp.7, 2016, https://doi.org/10.1517/14656566.2016.1154539
  14. Evodiamine induces apoptosis and enhances apoptotic effects of erlotinib in wild-type EGFR NSCLC cells via S6K1-mediated Mcl-1 inhibition vol.33, pp.2, 2016, https://doi.org/10.1007/s12032-015-0726-4
  15. Curative Surgery for Stage IA Small Cell Lung Cancer and Its Histological Evaluation vol.56, pp.3, 2016, https://doi.org/10.2482/haigan.56.205
  16. Enhanced activity of doxorubicin in drug resistant A549 tumor cells by encapsulation of P-glycoprotein inhibitor in PLGA-based nanovectors vol.7, pp.2, 2013, https://doi.org/10.3892/ol.2013.1711
  17. Analysis of Flora Distribution and Drug Resistance in Sputum Culture from Patients with Lung Cancer vol.641-642, pp.1662-8985, 2013, https://doi.org/10.4028/www.scientific.net/AMR.641-642.625
  18. Silencing of AP-4 inhibits proliferation, induces cell cycle arrest and promotes apoptosis in human lung cancer cells vol.11, pp.6, 2016, https://doi.org/10.3892/ol.2016.4451